A panelist discusses how autoimmune screening through detection of diabetes-specific autoantibodies serves as a critical tool for identifying pre-symptomatic type 1 diabetes (T1D), enabling earlier intervention before significant beta cell loss occurs and potentially changing the disease trajectory through timely management strategies.
In this second part of a video series, Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, described a common scenario where patients with severe atopic dermatitis must first try and fail multiple topical treatments, all while having widespread symptoms, before insurers will approve systemic therapies.
Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.
Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) therapies by identifying patient subgroups most likely to benefit from specific interventions. Artificial intelligence (AI) integration offers potential for earlier diagnosis, improved prognostication and personalized treatment optimization through data pattern recognition.
An expert discusses the existing gaps in atopic dermatitis (AD) management, promising areas of research to address unmet needs, and key takeaways from the discussion for the managed care audience regarding AD management.
An expert discusses key considerations dermatologists should keep in mind when integrating newer therapies into their clinical practice, including implementing protocols for patient monitoring and promoting treatment adherence.
Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.
Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, where he discussed these topics and more earlier this week.
Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival (PFS). Cemiplimab’s outcomes align well with other PD-1/PD-L1 inhibitors, influencing clinical decisions for its use as a first-line treatment.
Panelists discuss how, at their practices, histology, staging and ECOG performance status guide treatment decisions for advanced non-small cell lung cancer (NSCLC). Compared with EMPOWER-Lung 1, these factors remain crucial. Key biomarkers, such as PD-L1 expression, influence PD-1 inhibitor efficacy. In 2025, treatment options are more personalized with emerging therapies.
A panelist discusses how C-peptide serves as a critical biomarker of endogenous insulin production, providing clinicians with valuable insights into remaining beta cell function that can guide personalized treatment approaches and help predict disease progression in patients with type 1 diabetes (T1D).
Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review (ICER) addresses the possible gene therapies that we could see reach the market this year.
Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and Economic Review, described specialty drugs as high-cost treatments requiring complex handling or disease management and highlighted key upcoming approvals, including a new PCSK9 inhibitor for lipid lowering and tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, which could become the first in its class approved for multiple sclerosis.
Julie Patterson, Pharm.D., Ph.D., of the National Pharmaceutical Council, tells Managed Healthcare Executive at the annual AMCP meeting in Houston that the Inflation Reduction Act of 2022 is a policy that seems to be leading to more consequences than it is benefits.
At the AMCP 2025 meeting, Julie Patterson, Pharm.D., Ph.D., of the National Pharmaceutical Council, explained that the impact of the IRA drug negotiation program on patient access is still unclear, but early research shows that coverage for selected drugs has been strong. However, as Medicare Part D undergoes changes, there are concerns about how plan incentives, formulary design and utilization management might affect future access.
Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast differentiation and ECM production. Admilparant shows promising antifibrotic activity in preclinical models but requires phase 3 efficacy data. As a novel targeted therapy, it may complement existing antifibrotics, particularly for progressive phenotypes with high LPA1 expression.
At the AMCP 2025 annual meeting, Sean Shirk, Pharm.D., stressed the need for payers to stay informed and engaged with legislation to sustain site-of-service efforts despite growing restrictions.
Co-presenter, Sean Shirk, Pharm.D., director of specialty clinical solutions at Prime Therapeutics, discussed this topic during a presentation on legislative impacts on site of service at the AMCP 2025 annual meeting in Houston on Tuesday.
Connie Estep, Pharm.D., BCGP, director of specialty clinical solutions at Prime Therapeutics, presented on legislative impacts on site of service at this year's AMCP meeting in Houston.
An expert discusses the advancements in systemic and targeted therapies that have had the most significant impact on atopic dermatitis (AD) treatment in recent years as well as the cost-effectiveness and real-world outcomes of biologics and Janus kinase (JAK) inhibitors compared with traditional systemic therapies for AD
An expert discusses the most common barriers clinicians face when prescribing topical therapies for atopic dermatitis (AD) and their impact on patient adherence as well as strategies dermatologists can employ to navigate insurance coverage, prior authorization and step therapy to ensure patients receive appropriate care.
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has been studied extensively in patients with mildly reduced or preserved ejection fraction.
Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.
Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, reduced rescue medication use, fewer dermatology visits, and a favorable safety profile compared to standard treatments, supporting its role as a valuable non-steroidal topical option for long-term management.
Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.
In an interview with Managed Healthcare Executive, Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School, addressed the uncertainty of the bleeding risks of abelacimab compared to rivaroxaban and highlighted abelacimab’s safety profile.
In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, discusses lifestyle management and GLP-1s.
John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 per month would make the GLP-1s cost-effective as a prevention measure.
